BackKailera Therapeutics Overview

Kailera Therapeutics Current Cash

Kailera Therapeutics's current cash is $130M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$130.30M

Peer trimmed avg / median

Loading

Kailera Therapeutics Current Cash History

Loading

Kailera Therapeutics vs. peers: Current Cash Comparison

Loading

Kailera Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Kailera Therapeutics (KLRA) FAQ

The latest current cash for KLRA is $130M as of June 2026. Investors often review this figure alongside Kailera Therapeutics's historical trend and sector peers before judging valuation or financial health.

A current cash figure of $130M for KLRA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting KLRA's current cash ($130M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Kailera Therapeutics's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.